BACKGROUND: Attention Deficit Hyperactivity Disorder (ADHD) is a developmental disorder primarily characterized by co-existence of attentional problems and hyperactivity. Lisdexamfetamine dimesylate(LDX) has been authorized for ADHD treatment since2013 in Europe.
OBJECTIVES: The objective of this study is to provide utilization data for LDX in European countries.
METHODS: This is a multicountry drug utilization study based on a retrospective database analysis. Longitudinal electronic medical records databases(Germany: IMS Disease Analyzer; UK: CPRD),National Registries (Denmark, Sweden), prescription databases (Switzerland: IFAK/New Index) and prescription data derived from prescriber panels(Spain, Switzerland: IMS Prescribing Insights) were used. The study includes all patients who have been prescribed LDX at least once during the study period(March [first EU launch] 2013 – December 2014).
RESULTS: Overall, 11,369 patients with 40,374 prescriptions were included in the analysis. The majority of patients treated with LDX were males: Germany (78%), UK (82%), Spain (87%),Denmark (63%), Sweden (60%) and Switzerland(75%).Less than 1% of all patients were < 6 years. Proportion of patients >18 years with LDX was 4% in Spain,9% in Germany, 12% in UK, 45% in Denmark, 60%in Sweden and 70% in Switzerland. For 78% (Sweden) or ≥90% of patients (Germany, Spain, UK) an ADHD diagnosis was documented in the medical history in all countries with available in-formation in the database. Prescribed average daily dose (ADD) of LDX was within recommended range (30-70mg) for 97% to100% of patients, with a mean ADD of 41mg in Spain,44mg in Germany, 48mg in UK and about 45mg in Sweden. In Denmark and Switzerland recommended dose was not available in the database.
CONCLUSIONS: Findings indicate that LDX is mainly prescribed label compliant with respect to targeted patient group and dose regimen. Adult use is more common in Denmark, Sweden and Switzerland where use of LDX is licensed for adults.
